trichostatin A
Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
Cross Reference
Introduction
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with trichostatin A?
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with trichostatin A
PubChem Associated disorders and diseases
What pathways are associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with trichostatin A?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with trichostatin A?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with trichostatin A?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with trichostatin A?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with trichostatin A?
Mouse Model
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with trichostatin A
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Giannini G et al. | N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. | 2009 | Bioorg. Med. Chem. Lett. | pmid:19285395 |
| Lee S et al. | Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17588744 |
| Wang DF et al. | QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. | 2004 | Bioorg. Med. Chem. Lett. | pmid:14741273 |
| Desai D et al. | SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20167479 |
| Jose B et al. | Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. | 2004 | Bioorg. Med. Chem. Lett. | pmid:15454224 |
| Pabba C et al. | Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. | 2011 | Bioorg. Med. Chem. Lett. | pmid:21109435 |
| Gupta PK et al. | Inhibitors selective for HDAC6 in enzymes and cells. | 2010 | Bioorg. Med. Chem. Lett. | pmid:20947351 |
| Shinji C et al. | Design and synthesis of phthalimide-type histone deacetylase inhibitors. | 2005 | Bioorg. Med. Chem. Lett. | pmid:16137884 |
| Vasudevan A et al. | Heterocyclic ketones as inhibitors of histone deacetylase. | 2003 | Bioorg. Med. Chem. Lett. | pmid:14592473 |
| Charrier C et al. | Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. | 2007 | Bioorg. Med. Chem. Lett. | pmid:17897824 |
| Lavoie R et al. | Design and synthesis of a novel class of histone deacetylase inhibitors. | 2001 | Bioorg. Med. Chem. Lett. | pmid:11597413 |
| Tobias CA et al. | Improved recombinant retroviral titers utilizing trichostatin A. | 2000 | BioTechniques | pmid:11056820 |
| Seo H et al. | Modulation of immunoglobulin gene conversion in chicken DT40 by enhancing histone acetylation, and its application to antibody engineering. | 2007 | Biotechnol. Genet. Eng. Rev. | pmid:18059633 |
| Kalaiarasi A et al. | Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. | 2018 | Biotechnol. Lett. | pmid:29116558 |
| Liu X et al. | The improvement of adenovirus vector production by increased expression of coxsackie adenovirus receptor. | 2009 | Biotechnol. Lett. | pmid:19330491 |
| Kim HJ et al. | Enhancement of human mesenchymal stem cell differentiation by combination treatment with 5-azacytidine and trichostatin A. | 2016 | Biotechnol. Lett. | pmid:26341652 |
| Menegola E et al. | Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. | 2005 | Birth Defects Res. B Dev. Reprod. Toxicol. | pmid:16193500 |
| Rahman MM et al. | Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. | 2003 | Blood | pmid:12511413 |
| Zhou DC et al. | Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. | 2002 | Blood | pmid:11830487 |
| Milhem M et al. | Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. | 2004 | Blood | pmid:14976039 |
| Cao H et al. | Induction of human gamma globin gene expression by histone deacetylase inhibitors. | 2004 | Blood | pmid:12920038 |
| Hebbel RP et al. | The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. | 2010 | Blood | pmid:20053759 |
| Sadoul K et al. | HDAC6 controls the kinetics of platelet activation. | 2012 | Blood | pmid:22955928 |
| Hambach L et al. | Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. | 2009 | Blood | pmid:19096014 |
| Petti MC et al. | Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. | 2002 | Blood | pmid:12130525 |
| Araki H et al. | Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. | 2007 | Blood | pmid:17185465 |
| Chaurasia P et al. | Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. | 2011 | Blood | pmid:21355088 |
| Jamaluddin MD et al. | Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. | 2007 | Blood | pmid:17698632 |
| Wang X et al. | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. | 2010 | Blood | pmid:20858855 |
| Witt O et al. | Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. | 2003 | Blood | pmid:12393499 |
| Smith RD et al. | Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. | 2000 | Blood | pmid:10648397 |
| Ishiguro K and Sartorelli AC | Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. | 1998 | Blood | pmid:9834245 |
| Li X et al. | Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. | 2009 | Blood | pmid:19864643 |
| Gao C et al. | Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. | 2013 | Blood | pmid:23287862 |
| Chen Z et al. | BCL11A represses HBG transcription in K562 cells. | 2009 Mar-Apr | Blood Cells Mol. Dis. | pmid:19153051 |
| Swank RA et al. | The histone deacetylase inhibitor, trichostatin A, reactivates the developmentally silenced gamma globin expression in somatic cell hybrids and induces gamma gene expression in adult BFUe cultures. | 2003 May-Jun | Blood Cells Mol. Dis. | pmid:12737942 |
| Xu ZM et al. | The novel gene LRP15 is regulated by DNA methylation and confers increased efficiency of DNA repair of ultraviolet-induced DNA damage. | 2008 | BMB Rep | pmid:18377727 |
| Viñuelas J et al. | Quantifying the contribution of chromatin dynamics to stochastic gene expression reveals long, locus-dependent periods between transcriptional bursts. | 2013 | BMC Biol. | pmid:23442824 |
| Nordström L et al. | DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. | 2015 | BMC Cancer | pmid:25880212 |
| Mossman D et al. | Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. | 2010 | BMC Cancer | pmid:20618997 |
| Wu Y et al. | Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. | 2010 | BMC Cancer | pmid:20132554 |
| Acun T et al. | SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation. | 2011 | BMC Cancer | pmid:21645397 |
| DÃaz-Núñez M et al. | Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. | 2016 | BMC Cancer | pmid:27549189 |
| Mazières J et al. | Epigenetic regulation of RhoB loss of expression in lung cancer. | 2007 | BMC Cancer | pmid:18047684 |
| Arce L et al. | Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. | 2009 | BMC Cancer | pmid:19460168 |
| Tombolan L et al. | Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma. | 2016 | BMC Cancer | pmid:27842508 |
| Dávalos-Salas M et al. | Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter. | 2011 | BMC Cancer | pmid:21663659 |
| Kim TW et al. | Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer. | 2013 | BMC Cancer | pmid:24160266 |
| Mühlethaler-Mottet A et al. | Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. | 2006 | BMC Cancer | pmid:16930472 |
| Puppin C et al. | HEX expression and localization in normal mammary gland and breast carcinoma. | 2006 | BMC Cancer | pmid:16854221 |